Literature DB >> 10882656

Serologic testing for celiac disease in the United States: results of a multilaboratory comparison study.

J A Murray1, J Herlein, F Mitros, J A Goeken.   

Abstract

The aim of this study was to compare the efficiencies of six reference laboratories for serologic testing for celiac disease. Serum from 20 patients with untreated celiac disease and from 20 controls was thawed, divided, and distributed to each participating laboratory, which performed endomysial antibody tests. Five laboratories also performed antigliadin antibody tests. Sensitivity for endomysial antibody immunoglobulin A (IgA) varied from 57 to 90%. In all laboratories, the specificity for celiac disease was 100%. The sensitivity and specificity for both IgA and IgG antigliadin antibody varied significantly. When results from all three tests were combined in each laboratory, sensitivity was 90 to 100%. The specificity for endomysial antibody was 100% in the laboratories. Sensitivity was less than reported previously. Standardization of these tests is needed in the United States.

Entities:  

Mesh:

Year:  2000        PMID: 10882656      PMCID: PMC95918          DOI: 10.1128/CDLI.7.4.584-587.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  25 in total

Review 1.  Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue').

Authors:  M N Marsh
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

2.  Celiac disease and selective immunoglobulin A deficiency.

Authors:  F Cataldo; V Marino; G Bottaro; P Greco; A Ventura
Journal:  J Pediatr       Date:  1997-08       Impact factor: 4.406

3.  Anti-reticulin antibodies in childhood coeliac disease.

Authors:  P P Seah; L Fry; M A Rossiter; A V Hoffbrand; E J Holborow
Journal:  Lancet       Date:  1971-09-25       Impact factor: 79.321

4.  Relationship of endomysial antibodies to jejunal mucosal pathology: specificity towards both symptomatic and asymptomatic celiacs.

Authors:  T M Rossi; V Kumar; A Lerner; L A Heitlinger; N Tucker; J Fisher
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988 Nov-Dec       Impact factor: 2.839

5.  Disease specificity and dynamics of changes in IgA class anti-endomysial antibodies in celiac disease.

Authors:  A Kapuscinska; T Zalewski; T P Chorzelski; J Sulej; E H Beutner; V Kumar; T Rossi
Journal:  J Pediatr Gastroenterol Nutr       Date:  1987 Jul-Aug       Impact factor: 2.839

6.  Comparison of IgA-class reticulin and endomysium antibodies in coeliac disease and dermatitis herpetiformis.

Authors:  O Hällström
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

7.  R1 reticulin antibodies: markers of celiac disease in children on a normal diet and on gluten challenge.

Authors:  R Lazzari; U Volta; F B Bianchi; A Collina; E Pisi
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984-09       Impact factor: 2.839

8.  Screening for coeliac disease in adults by simultaneous determination of IgA and IgG gliadin antibodies.

Authors:  S U Friis; E Gudmand-Høyer
Journal:  Scand J Gastroenterol       Date:  1986-11       Impact factor: 2.423

9.  Endomysial antibody: is it the best screening test for coeliac disease?

Authors:  M Ferreira; S L Davies; M Butler; D Scott; M Clark; P Kumar
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

10.  Predictive value for coeliac disease of antibodies to gliadin, endomysium, and jejunum in patients attending for jejunal biopsy.

Authors:  S A McMillan; D J Haughton; J D Biggart; J D Edgar; K G Porter; T A McNeill
Journal:  BMJ       Date:  1991-11-09
View more
  16 in total

1.  Diagnostic approach to a patient with suspected celiac disease: a cost analysis.

Authors:  G C Harewood; J A Murray
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 2.  Do you still need a biopsy to diagnose celiac disease?

Authors:  S Guandalini; P Gupta
Journal:  Curr Gastroenterol Rep       Date:  2001-10

3.  Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy.

Authors:  Julian A Abrams; Beverly Diamond; Heidrun Rotterdam; Peter H R Green
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

4.  A case of diarrhea, ataxia, and capsule endoscope retention.

Authors:  Richard Guerrero; Luis F Lara; Jeffrey D Browning
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

5.  Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up.

Authors:  Umberto Volta; Alessandro Granito; Erica Fiorini; Claudia Parisi; Maria Piscaglia; Georgios Pappas; Paolo Muratori; Francesco B Bianchi
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 6.  Coeliac disease and the videocapsule: what have we learned till now.

Authors:  Edward J Ciaccio; Suzanne K Lewis; Govind Bhagat; Peter H Green
Journal:  Ann Transl Med       Date:  2017-05

7.  Detection of autoantibodies against actin filaments in celiac disease.

Authors:  B Porcelli; F Ferretti; C Vindigni; C Scapellato; L Terzuoli
Journal:  J Clin Lab Anal       Date:  2013-01-04       Impact factor: 2.352

Review 8.  Is enteroscopy necessary for diagnosis of celiac disease?

Authors:  Taylan Kav; Bulent Sivri
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

9.  Serological and clinical comparison of children and adults with anti-endomysial antibodies.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Nedeljko Radlovic; Ivana Davidovic; Ljiljana Sofronic; Milan Spuran; Marjan Micev; Milos M Nikolic
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

10.  Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study.

Authors:  Marjorie M Walker; Joseph A Murray; Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Mauro D'Amato; Brian Lahr; Nicholas J Talley; Lars Agreus
Journal:  Gastroenterology       Date:  2010-04-13       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.